Literature DB >> 18512075

Chemotherapy of chronic indeterminate Chagas disease: a novel approach to treatment.

Paola Carolina Bazán1, María Silvina Lo Presti, Héctor Walter Rivarola, María Fernanda Triquell, Ricardo Fretes, Alicia Ruth Fernández, Julio Enders, Patricia Paglini-Oliva.   

Abstract

Treatment of Chagas disease is a controversial issue because the available drugs are highly toxic. Clomipramine is a tricyclic antidepressant drug that inhibits Trypanosoma cruzi's trypanothione reductase, provoking the death of the parasite and preventing the cardiac damage when used for the treatment of acutely infected mice. Here, we studied the effectiveness of clomipramine (5 mg/kg/day for one month) as chemotherapy for T. cruzi-infected mice in the chronic indeterminate stage of the infection. The animals were analyzed in the cardiac chronic phase. Survival of treated animals was 84% while for the untreated ones was 40%; most of the animals presented electrocardiographic abnormalities. Affinity and density of cardiac beta receptors from infected and treated mice were similar to those in the indeterminate phase, showing that clomipramine treatment stopped the increment of functional alterations provoked by the infection, while untreated mice presented affinity and density significantly diminished. Hearts from infected and untreated mice in the chronic stage presented mononuclear cells, necrosis and fiber dissolution while hearts from treated animals showed only isolated inflammatory infiltrates. Present results demonstrate that clomipramine used in the chronic indeterminate phase of the T. cruzi infection modified the natural evolution of the chagasic cardiopathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18512075     DOI: 10.1007/s00436-008-1029-x

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  28 in total

Review 1.  Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine.

Authors:  Rodolfo Viotti; Carlos Vigliano
Journal:  Expert Rev Anti Infect Ther       Date:  2007-08       Impact factor: 5.091

Review 2.  Trypanosoma cruzi-induced molecular mimicry and Chagas' disease.

Authors:  N Gironès; H Cuervo; M Fresno
Journal:  Curr Top Microbiol Immunol       Date:  2005       Impact factor: 4.291

3.  Trypanosoma cruzi: chemotherapeutic effects of clomipramine in mice infected with an isolate obtained from an endemic area.

Authors:  H W Rivarola; J M Bustamante; S Lo Presti; A R Fernández; J E Enders; S Gea; R Fretes; P Paglini-Oliva
Journal:  Exp Parasitol       Date:  2005-10       Impact factor: 2.011

4.  Pharmacological and contractile response of myocardium of Chagasic albino Swiss mice.

Authors:  P Paglini-Oliva; A Fernández-Culasso; J L Lacuara
Journal:  Acta Physiol Pharmacol Latinoam       Date:  1987

5.  Arylfurans as potential trypanosoma cruzi trypanothione reductase inhibitors.

Authors:  Renata B de Oliveira; Aline B M Vaz; Rosana O Alves; Daniel B Liarte; Claudio L Donnici; Alvaro J Romanha; Carlos L Zani
Journal:  Mem Inst Oswaldo Cruz       Date:  2006-03       Impact factor: 2.743

6.  Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.

Authors:  Simone Garcia; Carolina O Ramos; Juliana F V Senra; Fabio Vilas-Boas; Maurício M Rodrigues; Antonio C Campos-de-Carvalho; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 7.  Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina.

Authors:  Sergio Sosa-Estani; Elsa Leonor Segura
Journal:  Curr Opin Infect Dis       Date:  2006-12       Impact factor: 4.915

8.  Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic chagas heart disease.

Authors:  Alejandro G Schijman; Carlos A Vigliano; Rodolfo J Viotti; Juan M Burgos; Silvia Brandariz; Bruno E Lococo; Maria I Leze; Hector A Armenti; Mariano J Levin
Journal:  Am J Trop Med Hyg       Date:  2004-02       Impact factor: 2.345

Review 9.  Metabolism and functions of trypanothione in the Kinetoplastida.

Authors:  A H Fairlamb; A Cerami
Journal:  Annu Rev Microbiol       Date:  1992       Impact factor: 15.500

10.  Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment.

Authors:  M A Segura; E Molina de Raspi; M A Basombrio
Journal:  Mem Inst Oswaldo Cruz       Date:  1994 Apr-Jun       Impact factor: 2.743

View more
  3 in total

1.  Relevance of Trypanothione Reductase Inhibitors on Trypanosoma cruzi Infection: A Systematic Review, Meta-Analysis, and In Silico Integrated Approach.

Authors:  Andréa Aparecida Santos Mendonça; Camila Morais Coelho; Marcia Paranho Veloso; Ivo Santana Caldas; Reggiani Vilela Gonçalves; Antônio Lucio Teixeira; Aline Silva de Miranda; Rômulo Dias Novaes
Journal:  Oxid Med Cell Longev       Date:  2018-10-24       Impact factor: 6.543

2.  Physical Exercise Promotes a Reduction in Cardiac Fibrosis in the Chronic Indeterminate Form of Experimental Chagas Disease.

Authors:  Yasmin Pedra-Rezende; Juliana M C Barbosa; Ana Cristina S Bombaça; Luiza Dantas-Pereira; Daniel Gibaldi; Glaucia Vilar-Pereira; Hílton Antônio Mata Dos Santos; Isalira Peroba Ramos; Natália Lins Silva-Gomes; Otacilio C Moreira; Joseli Lannes-Vieira; Rubem F S Menna-Barreto
Journal:  Front Immunol       Date:  2021-11-04       Impact factor: 7.561

3.  Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi.

Authors:  Joseph D Planer; Matthew A Hulverson; Jennifer A Arif; Ranae M Ranade; Robert Don; Frederick S Buckner
Journal:  PLoS Negl Trop Dis       Date:  2014-07-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.